The ability of IPD-1151T to suppress the induction of human IgE synthesis was investigated with an in vitro model of IgE production mediated by an allergen-specific helper T cell line (SN-4) from a patient allergic to Japanese cedar pollen. IPD-1151T induced a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis. In addition, the production of interleukin 4 (IL-4) by Cry j 1-ac tivated SN-4 as well as that by phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) of normal donors was inhibited in a concentration-dependent manner by the agent. Interestingly, IPD-1151T clearly depressed PHA-induced expression of IL-4 mRNA in normal PBMC, indicating that this agent inhibits IL-4 gene transcription. However, IPD-1151T had no antagonistic action on IL-4, since neither IL-4-induced expression of low-affinity IgE receptor (Fc e RII/CD23) on normal B cells nor soluble Fc e RII release from IL-4-stimulated B cells was affected by the agent. On the other hand, IPD-1151T had no effect on the production of interferon-y by both Cry j 1-stimulated SN-4 and anti-CD3 monoclonal anti body-activated T cells of normal donors. These results suggest that the selective suppression of IgE syn thesis by IPD-1151T results from the inhibition of IL-4 production by T cells at the gene level.
In the preceding paper (1), (±)-[2-[4-(3-ethoxy-2-hydroxy propoxy) phenylcarbamoyl]ethyl] dimethylsulfonium p toluenesulfonate (IPD-1151T, suplatast tosilate) has been demonstrated to be effective in selectively suppressing the murine IgE antibody response, possibly by interfering with the production of T cell-derived interleukin 4 (IL-4). Since it has been reported that IL-4 is essentially required for the induction of IgE synthesis both in mice and hu mans (2 4) , additional studies with the human system are needed to evaluate the IgE-suppressive activity of IPD 1151 T. To this end, we have developed an in vitro model of human IgE synthesis mediated by an allergen-specific and IL-4-producing helper T cell line (TCL), named SN 4, from a patient allergic to Japanese cedar pollen (5) . In deed, SN-4 is a helper TCL capable of inducing the synthe sis of IgE and IgG in both autologous and allogeneic B cells in an HLA-DR-restricted manner upon stimulation with Cry j 1, known to be the purified major allergen (6, 7) .
First, the present study was performed to determine the capacity of IPD-1151T to suppress the induction of hu man IgE synthesis mediated by SN-4, a Cry j 1-specific helper TCL. The results obtained indicate that IPD 1151T induces the highly selective suppression of Cry j 1 dependent IgE synthesis in autologous B cell cultures mediated by SN-4 through the inhibition of IL-4 produc tion. Next, the mechanisms responsible for the inhibition of IL-4 production by IPD-1151T were preliminarily in vestigated with activated T cells of normal donors. An im portant message from the present study is that IPD-1151T inhibits IL-4 gene expression.
MATERIALS AND METHODS

Materials
Cry j 1 was purified from the crude extract of the Japanese cedar (Cryptomeria japonica) pollen as described elsewhere (6) . Phytohemagglutinin (PHA, type P) was purchased from Serva. Human recombinant (r) IL-2, IL-4 and interferon-y (IFN-y) were obtained from Genzyme. Mitomycin C (MMC), cycloheximide, puromy cin, 2-aminoethylisothiouronium bromide (AET) and 2 mercaptoethanol (2-ME) were purchased from Sigma. Cyclosporin A (CyA) was a kind gift of Sandoz Laborato ries. It was dissolved in 50% ethanol (5 mg/ml) and dilut ed by culture medium immediately before use; the final concentration of ethanol was 0.01076. Dulbecco's modified Eagle medium and nonessential amino acids were obtained from Gibco, and agar noble was from Difco Laboratories.
Anti-CD3 (OKT3), anti-CD11b (OKM1) and anti-CD21 (OKB7) monoclonal antibodies (mAbs) were purchased from Ortho Laboratories. Anti CD4 (anti-leu-3a), anti-CD8 (anti-leu-2b) and anti-CD14
(anti-leu-M3) mAbs were purchased from Becton Dickin son. Anti-CD20 (anti-B1), anti-CD29 (anti-4B4) and anti CD45RA (anti-2H4) mAbs were obtained from Coulter Immunology. Anti-Fc E RII/CD23 mAbs (10/3, 11/4 and 12/2) were produced in our laboratory. The production and characterization of these three anti-CD23 mAbs have been described in detail (8) . Human IL-4 cDNA was cloned in our laboratory according to the method of Yokota et al. (9) . The cDNA probe specific for human /3 actin was purchased from Wako. These two probes were labeled by random hexanucleotide priming with [32P] dCTP and then heat-denatured. All of the materials used in this study were exactly as described in the preceding paper (1).
Cell preparation
Human peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by centrifu gation on a Ficoll-sodium metrizoate gradient, and T and B cell fractions were separated from PBMC by rosetting with AET-treated sheep erythrocytes, as previously described (10, 11) . To obtain purified T cells, rosetting cells were incubated with anti-CD21 and anti-CD 11 b mAbs and rabbit complement; they contained neither CD20+ B cells nor CD 14+ monocytes as analyzed by flow cytometry (FACS 440, Becton Dickinson) equipped with argon laser running at 488 nm. To obtain the B cell enriched fractions, non-rosetting cells were treated with anti-CD3 mAb and rabbit complement; they contained 20 to 30% CD14+ monocytes but less than 1% CD3+ T cells. To obtain further highly purified B cells, the B cell enriched fractions were depleted of monocytes by adher ence to plastic dishes and then treated with anti-CD llb mAb and complement. Highly purified B cell fractions contained more than 90% CD20+ B cells.
Isolation of allergen-specific helper TCL (SN-4)
SN-4, a Cry j 1-specific helper TCL, was isolated from PBMC of one patient allergic to Japanese cedar pollen by the use of a soft-agar cloning technique as previously described (5) . Briefly, PBMC obtained from the patient were cultured for 5 days with 50,ug/ml of Cry j 1 at a den sity of 1 x 106 cells/ml in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS), 1 % nonessential amino acids, 100 U/ml penicillin, 100,ug/ml streptomy cin, 5 MM L-glutamine and 5 x 10-5 M 2-ME (culture medium). Viable cells were harvested, resuspended in Dul becco's modified Eagle medium, and then cultured in a two-layer soft-agar system in 35-mm plastic dishes; the up per agar layer (0.85 ml of 0.32% agarose) was composed of 2 x 105 autologous antigen-presenting cells (APC, B cell-enriched fractions pretreated with 50 pg/ml of MMC) and 10% FCS; the lower agar layer (2.5 ml of 0.5% agar) was composed of 50 pg/ml of Cry j 1 and 10% FCS. Af ter culture for 5 days, the colonies in the upper layer were picked up and then placed in 96-well round-bottomed microplates with 2 x 105 cells/ml of fresh autologous APC in a volume of 0.2 ml of culture medium containing 50 pg/ml of Cry j 1 and 100 U/ml of rIL-2. Every 3 days, one-half of the medium was replaced by fresh culture medium containing rIL-2. After sufficient growth, TCLs were harvested, adjusted to 1 x 105 cells/ml, and then cul tured with 50 pg/ml of Cry j 1, 100 U/ml of rIL-2 and 1 X 105 cells/ml of fresh autologous APC in 96-well flat bottomed microplates. Cultures were fed every 3 days, and TCLs were further expanded in culture medium con taining rIL-2 with many cycles of stimulation with Cry j 1 in the presence of autologous APC. Several TCLs were maintained for 3 to 6 months, and one TCL, named SN 4, was finally selected on the basis of its excellent ability to proliferate in response to only Cry j 1. Phenotypic anal ysis by FACS showed that SN-4 belongs to the helper/ inducer subsets of T cells. Indeed, SN-4 was positive for CD3, CD4 and CD29, but negative for CD8 and CD45RA. For the functional assay, SN-4 was rested in culture medium containing rIL-2 for 7 days after the last stimulation with Cry j 1.
Culture condition for production of IgE and IgG
Autologous B cell-enriched fractions (1 x 105 cells/ well) were cultured in the presence of SN-4 (4 x 104 cells/well) with 50 pg/ml of Cry j 1 in a total volume of 0.2 ml in round-bottomed, 96-well microplates at 371C. To estimate the passive release of preformed IgE and IgG into the culture supernatant, both cycloheximide and puromycin were added to some cultures (10, 11) . After 10 days, the culture supernatant was pooled from three wells, and IgE and IgG concentrations were measured by a solid-phase sandwich radioimmunoassay (RIA) as previ ously described (10, 11) .
Assay for cytokines
The cultures for cytokine production were set up at 37'C as follows: the mixtures of SN-4 and autologous APC (each 1 x 105 cells/well) were cultured for 3 days with 50,ug/ml of Cry j 1 in a total volume of 0.2 ml in round-bottomed microplates; PBMC (2 x 105 cells/well) from normal donors were cultured for 24 hr with 10 ,ug/ml of PHA in a total volume of 0.2 ml in flat-bot tomed, 96-well microplates; and purified T cells (1 x 105 cells/well) from normal donors were cultured in a total volume of 1 ml for 24 hr with anti-CD3 mAb that had been immobilized on flat-bottomed, 24-well plates at a concentration of 5,ug/ml. Cytokines in the culture super natants were quantitatively assayed by the following com mercially available kits: IL-4 (Quantikine human IL-4 ELISA kit, Research and Diagnosis System Inc.) and IFN-y (specific RIA kit, Centcor). The sensitivity of the as say was 30 pg/ml for IL-4 and 1 U/ml for IFN-y.
Fc e RII expression
Highly purified B cells from normal donors were sus pended in culture medium at a density of 1 x 106 cells/ml, and the cells were cultured in the absence or presence of 100 U/ml rIL-4 for 3 days at 371C. The cells were washed and then incubated with biotinylated-12/2 (1 pg/105 cells) for 90 min at 4C. After washing, the cells were further in cubated with phycoerythrin-conjugated streptravidin for 30 min at 41C. They were washed again with cold staining buffer, and 104 cells were analyzed by single-color FACS.
Assay for soluble Fc e RII
Highly purified B cells from normal donors were cul tured under conditions identical to those described above. Soluble Fc E RII in the culture supernatant was quantita tively measured by a sensitive solid-phase sandwich RIA with the use of two different anti-CD23 mAbs, 10/3 and 11/4, that recognize a different epitope of Fc a RII, as previously described (8) . Briefly, polyvinyl microplate wells were coated with 10 pg/ml of 10/3, and their un bound sites were blocked by incubation with 10% FCS. After washing, samples were incubated overnight in the wells. The plates were washed, and then 125I-labeled 11/4 was added to each well. After incubation for 8 hr, the wells were washed thoroughly, and the radioactivity was determined by a gamma counter. The sensitivity of the as say was 12.5 pg/ml when the purified soluble Fc E RII was used as a standard.
Northern blot analysis of IL-4 mRNA PBMC from normal donors at a density of 1 x 106 cells/ml were stimulated with 10 pg/ml of PHA in a total volume of 1 ml in flat-bottomed, 24-well plates. After cul ture for 6 hr, total RNA was extracted from the cells by the single step method (12) . Twenty micrograms of total RNA was electrophoresed in 1 % agarose gel containing 6% formaldehyde, and then transferred to nylon mem branes. Membranes were hybridized with a 32P-labeled cDNA probe of human IL-4 for 24 hr at 451C. Northern blot analysis for the human fl-actin control were also per formed on membranes transferred from gels prepared in parallel from the same RNA samples. Membranes were washed, air-dried, and then exposed to Kodak XAR-5 films with intensifier screens for 5 days at 701C. Densito metric analysis was carried out with a video densitometer (BioRad model 620). Autologous B cell-enriched fractions were cultured in the absence or presence of IPD 1151T for 10 days with SN-4 and Cry j 1. Each value indicates the mean of duplicate assays. The mean coefficient of value was less than 10%10.
RESULTS
Effect on IgE synthesis mediated by SN-4
SN-4 has been demonstrated to be a Cry j 1-specific and HLA-DR-restricted helper TCL capable of inducing the synthesis of both IgE and IgG in autologous B cells as well as in HLA-DRw9-matched allogeneic B cells of nor mal donors (5) . Here, autologous B cell-enriched frac tions containing monocytes were cultured in the absence or presence of IPD-1151T with SN-4 and Cry j 1 for 10 days, and the IgE-suppressive activity of the agent was evaluated in this culture system. Table 1 shows the results obtained in two different experiments. The induction of Cry j 1-dependent IgE synthesis mediated by SN-4 was suppressed in a concentration-dependent manner by IPD 1151T (1 and 10µg/ml). In contrast, this agent had only a minimal effect on the IgG response. Indeed, 10,ug/ml of IPD-1151T, although capable of inducing 56-72% sup pression of the IgE synthesis, induced no more than ap proximately 10% suppression of the IgG synthesis. These results indicate that the suppression of human Ig synthe sis by IPD-1151T is highly specific for the IgE isotype. 
Effect on IL-4 production
Since the induction of IgE synthesis mediated by SN-4 has been shown to be absolutely dependent upon the production of endogeneous IL-4 (5), we first studied whether IPD-1151T inhibits IL-4 production by SN-4. Upon stimulation of SN-4 with Cry j 1 in the presence of autologous APC for 3 days, high levels of IL-4 were de tected in the culture supernatants. As illustrated in Fig. 1 , IL-4 production was inhibited in a concentration-depend ent manner by IPD-1151T (1 and 10 pg/ml), indicating that this agent is effective in inhibiting the production of IL-4 by SN-4. Next, the ability of IPD-1151T to inhibit IL-4 production was investigated in normal lymphocytes. To this end, PBMC from normal donors were stimulated in the absence or presence of IPD-1151T for 24 hr with PHA, one of the potent T cell mitogens. Table 2 summa rizes the results obtained in five different donors. IPD 1151 T at concentrations of 1 and 10µg/ml significantly in hibited IL-4 production by PHA-stimulated PBMC in a concentration-dependent fashion. To further study the mode of action of IPD-1151T upon IL-4 production at the gene level, IL-4 mRNA expression was examined by Northern blot analysis. In this experiment, normal PBMC were stimulated in the absence or presence of IPD-1151 T or CyA with PHA for 6 hr, and three independ ent experiments were performed for each Northern blot analysis. A representative result is shown in Fig. 2 . IPD 1151 T (10 ug/ml) clearly reduced the level of IL-4 mRNA with a size of 0.63 kb in PHA-stimulated PBMC. The level of f3-actin mRNA with a size of 1.9 kb, however, was not affected by IPD-1151T. Approximately 30% decrease in the relative density of IL-4 transcripts was observed in the culture with 10µg/ml of IPD-1151T, as determined by standardizing with the density of 8-actin mRNA (1.0 in the control versus 0.7±0.1 in the culture with the agent, mean ±S.E. of three experiments). These results in dicate that IPD-1151T inhibits the activation of the IL-4 gene without affecting the level of fl-actin mRNA. Almost complete inhibition of IL-4 mRNA expression was ob tained with CyA (1 pg/ml), which is known to inhibit the induction of cytokine gene transcription (13) .
Effect on IFN-y production SN-4 has been shown to produce not only high levels of IL-4 but also very small amounts of IFN-y (5) . Our preli minary approach was to first investigate the effect of IPD 1151T on IFN-y production by SN-4. In this experiment, the same culture supernatants obtained in two experi ments in which the ability of IPD-1151T to inhibit IL-4 production by SN-4 had been examined were used for the determination of IFN-y levels. One of these two culture supernatants contained detectable amounts of IFN-y, However, it must be noted that the sensitivity of the IFN-y assay is no more than 1 U/ml. Therefore, the effect of IPD-1151T on IFN-y production was further investigated in a culture system capable of producing the high levels of IFN-y. To this end, purified T cells from normal donors were cultured in the absence or presence of IPD-11151T or CyA for 24 hr with anti CD3 mAb that had been immobilized on the bottoms of the plastic wells. Indeed, normal T cells produced large amounts of IFN-y in response to anti-CD3 mAb. Table 3 summarizes the results obtained in five different donors.
IPD-1151T at concentrations of 1 and 10µg/ml had no effect on the production of IFN-y by T cells stimulated with anti-CD3 mAb. In contrast, CyA (lug/ml), a potent inhibitor of cytokine production, induced the marked in hibition of IFN-y production. Effect on rIL-4-induced Fc E RII expression and soluble Fc E RII release Highly purified B cells from normal donors were stimu lated in the absence or presence of IPD-1151T or IFN-y with rIL-4 for 3 days, and then analyzed for the expres sion of Fc e RII by means of single-color FACS. As shown in Fig. 3 , IFN-y (1,000 U/ml) but not IPD-1151T
(1 and 10 yg/ml) inhibited rIL-4-induced expression of Fc E RII on B cells. The levels of soluble Fc c RII in the cul ture supernatants were also measured by a sensitive solid phase RIA. As summarized in Fig. 4 , soluble Fc E RII re lease was not affected by IPD-1151T at any concentra tion, while it was strongly inhibited by the addition of IFN-y. These results indicate that in contrast to IFN-y, IPD-1151T has no antagonistic action on IL-4. 
DISCUSSION
In the present study, the IgE-suppressive activity of IPD-1151T was evaluated by establishing an in vitro model of human IgE production. To this end, we have generated SN-4, a Cry j 1-specific and HLA-DR-restrict ed CD4+ TCL, from a patient allergic to Japanese cedar pollen (5) . Upon stimulation with Cry j 1, SN-4 was able to induce the synthesis of both IgE and IgG in autologous B cell cultures. The induction of IgE synthesis mediated by SN-4 was suppressed in a concentration-dependent fashion by the addition of IPD-1151T to the cultures. The same treatment, however, had only a minimal effect on the IgG response, thus indicating that the suppression of human Ig synthesis by IPD-1151T is highly specific for the IgE isotype. This is consistent with the previous find ing (1) that IPD-1151T exerted a selective influence on the IgE antibody response in the mouse system.
Our previous analysis of has demonstrated that its IgE-inducing activity is related to the production of IL-4 required to activate B cells to synthesize IgE. More recent studies by several investigators (14-16) have clearly indicated that whereas human CD4+ T cell clones have different profiles of cytokine production, they are comparable to those of mouse Thl and Th2 subsets clas sified by Coffman and his group (17) . For example, aller gen-specific CD4+ T cell clones from allergic patients in duce the production of high levels of IL-4 but little or no production of IFN-y, indicating that they fit the Th2 pat tern. Indeed, SN-4 with aberrant ratios of IL-4 versus IFN-y production is most likely to be the equivalent of mouse Th2 cells. Interestingly, IL-4 production by SN-4 was inhibited in a concentration-dependent fashion by IPD-1151T, whereas IFN-y production was not affected. The great efficacy of IPD-1151T in inhibiting IL-4 produc tion thus reflects its IgE-suppressive activity, since the in duction of IgE synthesis mediated by SN-4 was shown to be strongly suppressed by adding anti-IL-4 antibody in culture (5) . This finding is in keeping with the previous report (1) that IPD-1151T exerted an inhibitory effect on murine IL-4 production by a Th2 clone. The observation that IPD-1151T significantly inhibited IL-4 production by PHA-stimulated PBMC of normal donors further confirms that this agent is indeed effective in inhibiting IL-4 production by human T cells. PHA is known to in duce the production of some cytokines, due to the activa tion of transcription of cytokine genes (18, 19) . To ex plore the mode of action of IPD-1151T in the inhibition of IL-4 production, Northern blot analysis was per formed in PHA-stimulated cells but not in SN-4 because it was difficult to obtain a supply of the patient's cells. We found that IPD-1151T clearly reduced the level of IL-4 mRNA in PHA-stimulated PBMC of normal donors, in dicating that the agent inhibits some stages of the cascade of events leading to IL-4 production at the gene level. Since IL-4 has been shown to have the site of processing of the signal sequence (9), the inhibitory activity of IPD 1151T on several proteases was also investigated.
However, this agent had no inhibitory effect on the activ ities of proteases such as trypsin, chymotrypsin and papain (data not shown). These results strongly suggest that IPD-1151T acts directly at the transcriptional level of the IL-4 gene, but not at the processing level of IL-4 secre tion.
Cytokine production involved in T cell activation has been demonstrated to be regulated by some immunosup pressive drugs such as CyA and FK506 (13, (20) (21) (22) . For example, both drugs are known to interact with peptidyl prolyl cis-trans isomerase and to inhibit cytokine produc tion at the gene level. Indeed, CyA was effective in inhibit ing IL-4 mRNA expression in PHA-stimulated PBMC of normal donors. Moreover, IFN-y production by normal T cells activated with immobilized anti-CD3 mAb was also inhibited by CyA. These findings indicate that the in hibition of cytokine production by CyA is not limited to IL-4 or IFN-y, as already confirmed by several investiga tors (13, 20, 21) . In contrast, IPD-1151T had no effect on IFN-y production by activated T cells. These results sup port the idea that the regulation of cytokine production by IPD-1151T is strikingly different from that by CyA. This idea further suggests that whereas CyA acts on both IFN-y-producing Th 1 and IL-4-producing Th2 cells, IPD-1151T acts selectively on Th2 cells. However, it must be emphasized that IPD-1151T has no antagonistic action on IL-4, since neither rIL-4-induced Fc c RII expression on B cells nor soluble Fc e RII release by rIL-4-stimulated cultures was affected by the agent. Therefore, it is most likely that Th2 cells responsible for IL-4 production are targets for the action of IPD-1151T. So far as is known at present, IPD-1151T may be the first drug that inhibits IL 4 but not IFN-y production. Interestingly, IPD-1151T is also demonstrated to inhibit not only IL-5 release from IL-2-activated T cells of patients with nonallergic hyperimmunoglobulinemia E who suffer from Kimura's disease (H. Enokihara, personal communication), but also IL-6 release from PHA-stimulated PBMC of normal donors (Y. Yanagihara, unpublished data). These obser vations in part confirm that IPD-1151T acts on Th2 cells but not on Thl cells.
In conclusion, the present study, together with the preceding paper (1), indicates that the IgE-suppressive ac tivity of IPD-1151T is essentially based on the inhibition of IL-4 production by Th2 cells. However, it is unclear why IPD-1151T acts selectively on Th2 subsets. Further studies are required to elucidate the molecular mecha nisms responsible for the inhibition of IL-4 production by IPD-1151T.
